SuperworthRevvity EPS RVTY
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jul 5, 2026
- $2.10
- Latest quarter, Q2 FY26
- $0.47
- +2% on a year earlier
- Fiscal year 2025
- $2.08
- −6% on the year before
Revvity's earnings per share was $2.10 over the twelve months to Jul 5, 2026, down 11% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.47, up 2% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 20% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $2.08 | −6% |
| FY2024 | $2.21 | −60% |
| FY2023 | $5.50 | +22% |
| FY2022 | $4.50 | −45% |
| FY2021 | $8.17 | +26% |
| FY2020 | $6.48 | +218% |
| FY2019 | $2.04 | −4% |
| FY2018 | $2.13 | −19% |
| FY2017 | $2.64 | +24% |
| FY2016 | $2.13 | +13% |
| FY2015 | $1.88 | +36% |
| FY2014 | $1.38 | −7% |
| FY2013 | $1.48 | +143% |
| FY2012 | $0.61 | +917% |
| FY2011 | $0.06 | −98% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.47 | +2% | $2.10 | |
| Q1 FY26 | $0.36 | +3% | $2.09 | |
| Q4 FY25 | $0.87 | +12% | $2.08 | |
| Q3 FY25 | $0.40 | −48% | $1.99 | |
| Q2 FY25 | $0.46 | +2% | $2.36 | |
| Q1 FY25 | $0.35 | +67% | $2.35 | |
| Q4 FY24 | $0.78 | +22% | $2.21 | |
| Q3 FY24 | $0.77 | +863% | $2.07 | |
| Q2 FY24 | $0.45 | +61% | $1.38 | |
| Q1 FY24 | $0.21 | −95% | $1.21 | |
| Q4 FY23 | $0.64 | −37% | $5.50 | |
| Q3 FY23 | $0.08 | −88% | $5.87 |
Against its peers
Companies in Medical - Diagnostics & Research nearest Revvity's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RVTYRevvity | $2.10 | −11% a year |
| MEDPMedpace | $17.05 | +27% a year |
| LHLabcorp | $12.09 | +33% a year |
| DGXQuest Diagnostics | $9.41 | +18% a year |
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| MTDMettler-Toledo International | $44.42 | +12% a year |
| CAICaris Life Sciences | $0.37 | |
| ILMNIllumina | $5.38 | −32% a year |
| IDXXIDEXX Laboratories | $14.22 | +18% a year |
| WATWaters | $4.01 | −64% a year |
| IQVIQVIA | $8.06 | +17% a year |
| Peer median | $8.83 |
Where Revvity ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Revvity
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.